


WHAT IS CLAIMED IS:

1. A compound of the formula:




5
wherein:

R₁ and R₂ are each independently -OR₉ or -NR₁₀R₁₁;

10 R₃, R₄, R₅, R₆, R₇, and R₈ are each independently hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, phenyl, phenoxy, benzyl, benzyloxy, C₃₋₈ cycloalkyl, N(R₁₂)₂, NHCO₁₃, S(O)_qC₁₋₁₀ alkyl, OH, or halogen; wherein C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, or C₂₋₁₀ alkynyl may be optionally substituted by COOH, OH, CO(CH₂)_nCH₃, CO(CH₂)_nCH₃, CH₂N(R₁₂)₂, or halogen; or R₃ and R₄, R₄ and R₅, R₆ and R₇, or R₇ and R₈ together may be -O-A-O- on contiguous carbons;

15 R₉ is C₁₋₁₀ alkylene, C₂₋₁₀ alkenylene, C₂₋₁₀ alkylidene, or C₂₋₁₀ alkynylene, all of which may be linear or branched or phenylene, all of which may be unsubstituted or substituted by one or more OH, COOH, alkoxy, NHR₁₂, N(R₁₂)₂, NHCO₁₃ or halogen; or R₉ is alkylsilyl, arylsilyl or alkylarylsilyl;

20 R₁₀ and R₁₁ are each independently C₁₋₁₀ alkylene, C₁₋₁₀ alkenylene, C₂₋₁₀ alkylidene, C₂₋₁₀ alkynylene, S(O)_q(R₁₄), C(O)NH(R₁₄), and C(O)_q(R₁₄), all of which may be linear or branched, phenylene or benzylene, all of which may be unsubstituted or substituted by one or more OH, COOH, alkoxy, NHR₁₂, N(R₁₂)₂, NHCO₁₃ or selected from the following group:



R₁₂ is hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, benzyl, or aryl, all of which may be unsubstituted or substituted by one or more OH, COOH, NH₂, secondary amine, tertiary amine, tetrazole, or PO₃H₂;

R₁₃ is C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, benzyl, or aryl, all of which may be unsubstituted or substituted by one or more OH, COOH, NH₂, secondary amine, tertiary amine, tetrazole, or PO₃H₂;

R₁₄ is C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₆ cycloalkyl, phenyl, and benzyl; wherein C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl maybe optionally substituted by COOH,

10 CO(CH₂)_nCH₃ or OH;

R₁₅ and R₁₆ are each independently hydrogen, aryl, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, and C₂₋₁₀ alkynyl, all of which may be unsubstituted or substituted by one or more CH₂OH, N(R₁₂)₂, NHCOR₁₃, OH, or halogen; wherein aryl is naphthyl, indolyl, pyridyl, thienyl, oxazolidinyl, oxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, 15 imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, thiadiazolyl, morpholinyl, piperidinyl, piperazinyl, pyrrolyl or pyrimidyl, all of which may be unsubstituted or substituted by one or more R₁₇, R₁₈, R₁₉; wherein if R₁₅ occurs without R₁₆, R₁₅ is not hydrogen;

R₁₇, R₁₈, R₁₉ are each independently hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, phenyl, benzyl, C₃₋₈ cycloalkyl, C₁₋₁₀alkoxy, S(O)_qC₁₋₁₀ alkyl, N(R₁₄)₂, NHCOR₆, OH, or halogen; wherein C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl may be optionally substituted by COOH, CO(CH₂)_nCH₃, CO(CH₂)_n, CH₂N(R₁₄)₂, OH or halogen;

5 X and Y are each independently -CH₂-, -(CH₂)₂-, -(CH₂)₃-, C=O, CH₂C(O), (CH₂)₂C(O), CH₂SO₂, and (CH₂)₂SO₂;

q is zero, one, two, or three;

n is an integer from zero to six;

or a diastereomer, enantiomer or pharmaceutically acceptable salts thereof.

10

2. The compound of claim 1 wherein X is CH₂(O), and Y is C=O.

3. The compound of claim 2 wherein R₃ and R₆ are H; and R₄, R₅, R₇ and R₈ are -OCH₃.

4. The compound of claim 3 which is 2-[2-(4-benzylpiperidine-1-carbonyl)-3-(3,4-dimethoxy-phenyl)-5,6-dimethoxy-indan-1-yl]-1-(4-benzylpiperidin-1-yl)-ethanone.

5. The compound of claim 3 which is 2-[3-(3,4-dimethoxyphenyl)-5,6-dimethoxy-2-[4-(2-ethoxyphenyl)-piperazin-1-carbonyl]-indan-1-yl]-1-[4-(2-ethoxyphenyl)-1-yl]-ethanone.

6. The compound of claim 1 wherein X is -(CH₂)₂-, and Y is -CH₂-.

25 7. The compound of claim 6 wherein R₃ and R₆ are H; and R₄, R₅, R₇ and R₈ are -OCH₃.

8. The compound of claim 1 wherein X is -(CH₂)₂-, and Y is -CH₂-; R₂ is -OCH₃; R₃ and R₆ are H; and R₄, R₅, R₇ and R₈ are -OCH₃.

30

9. The compound of claim 8 which is 1-benzyl-4-[2-[3-(3,4-dimethoxyphenyl)-5,6-dimethoxy-2-methoxymethyl-indan-1-yl]-ethyl]-piperazine.
10. A method of inhibiting P-glycoprotein-mediated transport, the method comprising
5 administering a compound of Formula I.
11. The method of claim 10 wherein the compound of Formula I is selected from the group presented in Table I.
- 10 12. The method of claim 11 wherein the compound has a percentage inhibition of Rhodamine 123 transport of at least 30%.
13. The method of claim 12 wherein the compound has a percentage inhibition of Rhodamine 123 transport of at least 50%.
14. The method of claim 13 wherein the compound has a percentage inhibition of Rhodamine 123 transport of at least 80%.
15. The method of claim 11 wherein the compound of Formula I is coadministered
20 with a pharmaceutical compound.
16. The method of claim 15 wherein the coadministered pharmaceutical compound has a percentage increase in cytotoxicity value of at least 30%.
- 25 17. The method of claim 16 wherein the coadministered pharmaceutical compound has a percentage increase in cytotoxicity value of at least 50%.
18. The method of claim 17 wherein the coadministered pharmaceutical compound has a percentage increase in cytotoxicity value of at least 80%.

19. Use of a compound of Formula I as an inhibitor of P-glycoprotein-mediated transport.
20. An inhibitor of P-glycoprotein-mediated transport comprising a compound of
5 Formula I.
21. A method of increasing bioavailability of an orally administered pharmaceutical compound, the method comprising:
orally coadministering (1) the pharmaceutical compound to a mammal in need of
10 treatment with the pharmaceutical compound and (2) a compound of Formula I in an amount of the compound of Formula I sufficient to provide bioavailability of the pharmaceutical compound in the presence of the compound of Formula I greater than bioavailability of the pharmaceutical compound in the absence of the compound of
5 Formula I.
22. A method of treating multidrug resistance in mammals, the method comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I.
- 20 23. A composition for inhibition of P-glycoprotein-mediated transport in mammals, the composition comprising a compound of Formula I in a pharmaceutically acceptable carrier.
24. A method of treating a tumor, the method comprising coadministering to a mammal in need thereof a therapeutically effective amount of a compound of Formula I and a therapeutic agent.
25. The method of claim 23 wherein the tumor is drug-resistant.

26. The method of claim 23 wherein the tumor has converted from drug-sensitive to drug-resistant.

27. The method of claim 23 wherein the therapeutic agent is a P-glycoprotein substrate.

28. The method of claim 23 is selected from doxorubicin, vinblastine, vincristine, epipodophyllotoxin, taxanes, paclitaxel, docetaxel, etoposide, tenopiside, colchicines, daunorubicin, topotecan, actinomycin D, mitoxantrone, mitomycin C.

10
29. A method of preventing multidrug resistance in tumor cells, the method comprising administering an effective amount of a compound of Formula I to the tumor cells.

15
30. A method of treating a tumor, the method comprising administering to a mammal in need thereof a therapeutically effective amount of a composition, the composition including a therapeutic agent and a compound of Formula I.

20
31. A method for increasing the sensitivity of tumor cells that have converted from sensitivity to therapeutic agents to resistance to the therapeutic agents, the method comprising coadministering to a mammal a therapeutically effective amount of a compound of Formula I and at least one of the therapeutic agents.

25
32. A pharmaceutical composition for increasing the sensitivity of tumor cells that have converted from sensitivity to therapeutic agents to resistance to the therapeutic agents, the pharmaceutical composition comprising (1) a therapeutically effective amount of a compound of Formula I, (2) at least one of the therapeutic agents, and (3) a pharmaceutically acceptable carrier.

33. A method of converting a non-orally bioavailable pharmaceutical composition into an orally bioavailable pharmaceutical composition, the method comprising formulating a composition including a compound of Formula I and the non-orally bioavailable pharmaceutical composition and optionally a pharmaceutically acceptable carrier.

5

34. An orally bioavailable pharmaceutical composition produced by the method of claim 33.

35. A method of delivering a pharmaceutical compound to the central nervous
10 system of a patient, the method comprising coadministering the pharmaceutical
compound with a compound of Formula I.